Stockreport

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]

NexImmune, Inc.  (NEXI) 
PDF to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it [Read more]